AIFF (Firefly Neuroscience, Inc.) Stock Market Reviews

crown

search

Read and share opinions on AIFF (Firefly Neuroscience, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

AIFF

Firefly Neuroscience, Inc.

clarify Software - Application

bookmark Technology

public United States

Sell Neutral Buy

Latest News

Firefly Neuroscience Reports Third Quarter 2025 Financial Results
Nov 12, 2025
Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America
Sep 5, 2025
Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform
Aug 26, 2025
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research
Jul 14, 2025
Firefly Neuroscience to be Added to the Russell Microcap® Index
Jun 23, 2025
Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
May 5, 2025
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million
Feb 21, 2025
Firefly Neuroscience Accepted into NVIDIA Connect Program
Feb 11, 2025
Firefly Neuroscience Congratulates Scientific Advisor, Dr. Christopher Wilson, Recipient of Prestigious UW Faculty of Engineering Award for Work on Superconducting Quantum Electronics
Feb 7, 2025
Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care
Jan 24, 2025
Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform
Jan 14, 2025
Firefly Neuroscience Closes on Financing of up to $12.4 Million
Dec 31, 2024
Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman
Dec 4, 2024
Firefly Neuroscience Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$0.18 loss in 3Q 2023)
Nov 16, 2024

Reviews